"Many entrepreneurs--especially returning entrepreneurs--want investors focused on what's best for the company, not what's best for the VC's portfolio . . .they don't want the goat rodeo, as I call it," states Geoff Schneider, Founder of Cava Capital. As an investor and operator for the past 30 years in the HALO sector, Geoff is also the Founder of Lymbr and investor in Fit Lab. Cava is currently raising a $40m pooled early stage capital fund. Pete and Geoff chat about the direction of fund, what they look for in new companies and entrepreneurs, why the typical VC "shoot the moon" strategy is problematic, different funding strategies in the VC world, and more. This is a must listen for any entrepreneur looking to learn more about early stage funding.
Geoff Schneider, Managing Director & Founder, Cava Capital
Get every new HALO Talks episode!
Each week, host Pete Moore sits down with the founders, operators, finance execs, and investors shaping the Health, Active Lifestyle, and Outdoor sector. Get new episodes in your inbox, no hype or BS, just the people building the sector.
Email has been submitted.
Recent Episodes
- Episode #618: Med Spa Expansion, Regulation, and Niches-Insights from Amanda Guarniere of GuardianMD
- Episode #617: From the Marines to Boardrooms-Jon Sheldon's Lessons on Leadership and Team Dynamics
- HALO Talks Fast Break: Revolutionizing Club Benefits-Amy Bach on Welld Health's Impact Across 10,000 Locations
- Episode #616: Regenerative Medicine, Market Education, and the Future of Wellness-Insights from Bill Quateman
- Episode #615: Inside Austin Pickle Ranch with Tim Klitch-Growth, Community, and Private Equity in Pickleball
- Episode #614: Building Sweathouz (SWTHZ)-Nico Varano on Scaling, Unit Economics, and Operational Excellence
- Episode #613: SoulFire's Formula-Blending Brand Identity, Community, and Profitability in Boutique Fitness
- Episode #612: Building Community Through Contrast Therapy-Carrie Bacon's Vision for 180 Degree Bathhouse
- Episode #611: Outpatient Innovation-Dr. Munir Ghesani Discusses Theranostics, Expansion, and Clinical Trials
- See all →